31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
A lower proportion of patients with cancer had palliative care initiated in the home (16 088 [14.5%]) compared with patients with chronic organ failure (6904 [32.8%]; absolute difference, -18.3%) or dementia (3922 [27.9%]; absolute difference, -13.4%). 5 key findings →
Design: cohort study Participants: 709 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings highlight the potential benefits of palliative care in some non-cancer illnesses. 5 key findings →
Design: cohort study Participants: 6,936 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study found that long-term exposure to air pollution was associated with a higher risk of dementia. 2 key findings →
Design: cohort study Participants: 4,590 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. 4 key findings →
Design: cohort study Participants: 6,896 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. 1 key finding →
Design: longitudinal study Participants: 20,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings support the short-term efficacy and safety of Lecanemab in early AD and highlight plasma biomarkers as a treatment-responsive biomarker. 3 key findings →
Design: cohort study Participants: 68 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study provides evidence that the effects of GLP-1 receptor agonists may extend beyond their known metabolic and cardioprotective benefits to include neuroprotection, associated with a decreased risk of developing various neurodegenerative disorders. 5 key findings →
Design: cohort study Participants: 102,935 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Consistent with previous reports, risk factors and prodromal features associated with PD included traumatic brain injury, odds ratio (OR), 1.62; 95% CI, 1.36-1.92; alcohol misuse, OR, 1.32; 95% CI, 1.21-1.44; hypertension, OR, 1.29; 95% CI, 1.26-1.31; anosmia, OR, 2.16; 95% CI, 1.59-2.93; and parasomnias (including RBD), OR, 1.62; 95% CI, 1.42-1.84. 4 key findings →
Design: cohort study Participants: 345 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this study, hearing loss was positively associated with a risk of dementia, especially in patients aged 45 to 64 years. 5 key findings →
Design: cohort study Participants: 8,135 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Mixed-effect models assessed rates of memory decline in relation to baseline plasma p-tau181, and whether plasma p-tau181 significantly predicted memory decline beyond widely available clinical and genetic data (age, sex, years of education, cardiovascular and metabolic conditions, and APOE ε 4 status). 5 key findings →
Design: longitudinal study Participants: 604 Evidence: moderate
Full summary, score breakdown and related studies → Original source
However, because these biomarkers are strongly associated with the emergence of Aβ pathology, it is difficult to determine the contribution of insoluble tau aggregates to the plasma p-tau signal in blood. 5 key findings →
Design: longitudinal study Participants: 1,294 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Potential DMT candidates at Butler MAP (n = 50), primarily diagnosed with mild cognitive impairment (n = 29 [58%]) or mild dementia (21 [42%]), were predominantly Aβ-positive (38 [76%]), and half (25 [50%]) were subsequently treated with aducanumab. 1 key finding →
Design: cohort study Participants: 150 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau181/NfL can potentially be used to monitor large-scale population interventions in CU individuals. 2 key findings →
Design: longitudinal study Participants: 257 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Application of biological age as a measure of an individual´s health status offers new perspectives into extension of both lifespan and healthspan. 4 key findings →
Design: cohort study Participants: 1,930 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Weight loss predicts AD CSF and PET biomarker results and may occur downstream to amyloid-β accumulation in preclinical AD, paralleling cognitive decline. 5 key findings →
Design: cohort study Participants: 2,743 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Midlife measurement of plasma Aβ may have utility as a blood-based biomarker indicative of risk for future cognitive impairment. 4 key findings →
Design: cohort study Participants: 2,284 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease neuropathology positivity was present in 86 (6%) participants based on p-tau217/Aβ42, 196 (15%) based on Aβ42/40, and 48 (4%) based on p-tau217, and was associated with worse performance on processing speed (standardised cognitive difference comparing Alzheimer's disease neuropathology positive to negative for Aβ42/40, p-tau217, and p-tau217/Aβ42 -0·54 to -0·25; p values 0·0001 to 0·0048) and executive function (-0·42 to -0·19; p values 0·0070 to 0·049). 3 key findings →
Design: cohort study Participants: 1,500 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Motor measures will be compared to a blood-based AD biomarker, phosphorylated tau 181 to develop an algorithm that classifies preclinical AD risk. 1 key finding →
Design: cohort study Participants: 1,382 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Noninvasive biomarkers of early neuronal injury may help identify cognitively normal individuals at risk of developing Alzheimer's disease (AD). 2 key findings →
Design: longitudinal study Participants: 196 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These outcomes illustrate the potential benefits of rasagiline on clinical and neuroimaging measures in patients with mild to moderate AD. 4 key findings →
Design: longitudinal study Participants: 50 Evidence: high
Full summary, score breakdown and related studies → Original source
The study team reported a significant change in diagnoses and patient medication when tau PET was added to an already extensive diagnostic workup that included cerebrospinal fluid AD biomarkers. 5 key findings →
Design: cohort study Participants: 878 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Accelerated biological aging, particularly DunedinPACE, was associated with increasing levels of plasma ADRD biomarkers over time. 4 key findings →
Design: longitudinal study Participants: 2,366 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Based on family informant reports and clinical observations, the median age at onset (AAO) among affected individuals in these pedigrees was 48.50 (44.0, 51.8) years. 5 key findings →
Design: longitudinal study Participants: 206 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher adherence to a MedDiet was associated with lower dementia risk, independent of genetic risk, underlining the importance of diet in dementia prevention interventions. 3 key findings →
Design: cohort Participants: 60,298 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this cohort study of a Korean population, decreased risk of dementia was associated with maintaining mild to moderate alcohol consumption, reducing alcohol consumption from a heavy to a moderate level, and the initiation of mild alcohol consumption, suggesting that the threshold of alcohol consumption for dementia risk reduction is low. 5 key findings →
Design: cohort Participants: 3,933,382 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events